JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Open Access
- 13 July 2017
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 130 (2), 115-125
- https://doi.org/10.1182/blood-2017-04-742288
Abstract
Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to become the centerpiece of therapy for myelofibrosis (MKeywords
This publication has 159 references indexed in Scilit:
- Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosisBlood Cancer Journal, 2014
- OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CMLNew England Journal of Medicine, 2013
- Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosisBlood, 2011
- Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasmsBlood Cancer Journal, 2011
- Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle controlOncogene, 2011
- Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemiaBlood, 2010
- HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humansJournal of Clinical Investigation, 2010
- Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cellsBlood, 2009
- Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activationExperimental Hematology, 2009
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005